Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70076 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Ashley L Lennox und 9 weiteren Autor:innen. Beteiligte Einrichtung: Geron Corporation, Foster City, CA, USA. Hauptthemen laut MEDLINE: Telomerase, Translational Research, Biomedical, Oligonucleotides. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Most cancers and neoplastic progenitor cells have elevated telomerase activity and preservation of telomeres that promote cellular immortality, making telomerase a rational target for the treatment of cancer. Imetelstat is a first‐in‐class, 13‐mer oligonucleotide that binds with high affinity to the template region of the RNA component of human telomerase and acts as a competitive inhibitor of human telomerase enzymatic activity. Pharmacokinetics, pharmacodynamics, exposure‐response analyses, efficacy, and safety of imetelstat have been evaluated in vitro, in vivo, and clinically in solid tumor and hematologic malignancies, including lower‐risk myelodysplastic syndromes (LR‐MDS) and myeloproliferative neoplasms. Imetelstat was approved in the United States in June 2024 for the treatment of adult patients with LR‐MDS with transfusion‐dependent anemia requiring four or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis‐stimulating agents, with a recommended dosing regimen of 7.1 mg/kg administered via 2‐h intravenous infusion every 4 weeks. In the pivotal trial, significantly more patients treated with imetelstat versus placebo achieved ≥8‐week and ≥24‐week red blood cell‐transfusion independence, and imetelstat was associated with a manageable safety profile characterized primarily by short‐lived and manageable neutropenia and thrombocytopenia. This mini‐review summarizes the mechanism of action, pharmacokinetic and pharmacodynamic characteristics, clinical development, and clinical efficacy and safety data of imetelstat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Geron Corporation, Foster City, CA, USA.
- Modeling Great Solutions Pharmaceutical Research & Studies, FZE, Dubai, UAE.
- Allucent, Cary, North Carolina, USA.
- Morcos Pharmaceutical Consulting, LLC, Marlboro, New Jersey, USA.
Zitieren
APA
Lennox, A. L., Huang, F., Behrs, M. K., González-Sales, M., Bhise, N., Wan, Y., Sun, L., Berry, T., Feller, F., & Morcos, P. N. (2024). Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science. Clinical and Translational Science. https://doi.org/10.1111/cts.70076
Vancouver
Lennox AL, Huang F, Behrs MK, González-Sales M, Bhise N, Wan Y, et al. Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 2024. doi:10.1111/cts.70076
BibTeX
@article{Lennox2024,
author = {Lennox, Ashley L and Huang, Fei and Behrs, Melissa Kelly and González-Sales, Mario and Bhise, Neha and Wan, Ying and Sun, Libo and Berry, Tymara and Feller, Faye and Morcos, Peter N},
title = {Imetelstat, a novel, first‐in‐class telomerase inhibitor: Mechanism of action, clinical, and translational science},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70076}
}
EUVIMED